Cargando…

Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)

Chronic immune activation in systemic sclerosis is supported by the production of a plethora of cytokines with proven regulatory activities of the immune responses. This study aimed to explore PBMCs’ cytokine profiles in SSc patients versus controls, as well as to investigate the balance between pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabo, Iulia, Badii, Medeea, Gaál, Ildikó O., Szabo, Robert, Popp, Radu A., Joosten, Leo A. B., Crişan, Tania O., Rednic, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572600/
https://www.ncbi.nlm.nih.gov/pubmed/37833885
http://dx.doi.org/10.3390/ijms241914438
_version_ 1785120271119679488
author Szabo, Iulia
Badii, Medeea
Gaál, Ildikó O.
Szabo, Robert
Popp, Radu A.
Joosten, Leo A. B.
Crişan, Tania O.
Rednic, Simona
author_facet Szabo, Iulia
Badii, Medeea
Gaál, Ildikó O.
Szabo, Robert
Popp, Radu A.
Joosten, Leo A. B.
Crişan, Tania O.
Rednic, Simona
author_sort Szabo, Iulia
collection PubMed
description Chronic immune activation in systemic sclerosis is supported by the production of a plethora of cytokines with proven regulatory activities of the immune responses. This study aimed to explore PBMCs’ cytokine profiles in SSc patients versus controls, as well as to investigate the balance between pro- and anti-inflammatory cytokines in association with disease duration. PBMCs were isolated from 18 SSc patients and 17 controls and further subjected to in vitro stimulation with lipopolysaccharide and heat-killed Candida albicans. Cytokine production was measured after 24 h and 7 days, respectively, using ELISA kits for interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-6, tumor necrosis factor (TNF), IL-10, IL-17, and interferon-gamma (IFN-gamma). IL-1 β, IL-6, and TNF levels were increased in SSc patients compared with healthy volunteers irrespective of the stimulus used. IL-1Ra and Il-17 concentrations were not statistically different between groups, even though a trend toward higher levels in patients compared with their matched controls was also observed. Most cytokines demonstrated a stable course with disease progression, except for IL-10 levels, which declined over time. In conclusion, the results of this pilot study reveal that in patients with SSc a persistently enhanced immune response is established and maintained regardless of stimulus or disease duration.
format Online
Article
Text
id pubmed-10572600
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105726002023-10-14 Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs) Szabo, Iulia Badii, Medeea Gaál, Ildikó O. Szabo, Robert Popp, Radu A. Joosten, Leo A. B. Crişan, Tania O. Rednic, Simona Int J Mol Sci Article Chronic immune activation in systemic sclerosis is supported by the production of a plethora of cytokines with proven regulatory activities of the immune responses. This study aimed to explore PBMCs’ cytokine profiles in SSc patients versus controls, as well as to investigate the balance between pro- and anti-inflammatory cytokines in association with disease duration. PBMCs were isolated from 18 SSc patients and 17 controls and further subjected to in vitro stimulation with lipopolysaccharide and heat-killed Candida albicans. Cytokine production was measured after 24 h and 7 days, respectively, using ELISA kits for interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-6, tumor necrosis factor (TNF), IL-10, IL-17, and interferon-gamma (IFN-gamma). IL-1 β, IL-6, and TNF levels were increased in SSc patients compared with healthy volunteers irrespective of the stimulus used. IL-1Ra and Il-17 concentrations were not statistically different between groups, even though a trend toward higher levels in patients compared with their matched controls was also observed. Most cytokines demonstrated a stable course with disease progression, except for IL-10 levels, which declined over time. In conclusion, the results of this pilot study reveal that in patients with SSc a persistently enhanced immune response is established and maintained regardless of stimulus or disease duration. MDPI 2023-09-22 /pmc/articles/PMC10572600/ /pubmed/37833885 http://dx.doi.org/10.3390/ijms241914438 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Szabo, Iulia
Badii, Medeea
Gaál, Ildikó O.
Szabo, Robert
Popp, Radu A.
Joosten, Leo A. B.
Crişan, Tania O.
Rednic, Simona
Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)
title Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)
title_full Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)
title_fullStr Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)
title_full_unstemmed Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)
title_short Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)
title_sort enhanced innate and acquired immune responses in systemic sclerosis primary peripheral blood mononuclear cells (pbmcs)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572600/
https://www.ncbi.nlm.nih.gov/pubmed/37833885
http://dx.doi.org/10.3390/ijms241914438
work_keys_str_mv AT szaboiulia enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT badiimedeea enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT gaalildikoo enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT szaborobert enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT poppradua enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT joostenleoab enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT crisantaniao enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs
AT rednicsimona enhancedinnateandacquiredimmuneresponsesinsystemicsclerosisprimaryperipheralbloodmononuclearcellspbmcs